(Adds details from the report, background)
Oct 30 (Reuters) - Britain’s health regulator has started accelerated reviews for COVID-19 vaccine candidates from Pfizer Inc and AstraZeneca Plc, according to a Bloomberg News report on Friday.
The Medicines and Healthcare Products Regulatory Agency (MHRA) is also conducting an expedited review of AstraZeneca's COVID-19 vaccine, developed along with the University of Oxford, the report said here.
AstraZeneca, Pfizer and MHRA did not immediately respond to Reuters request for comment.
AstraZeneca and Pfizer are among the frontrunners in the race to develop a vaccine for the new coronavirus, including, Johnson & Johnson and Moderna Inc. Their vaccine candidates are in late-stage trials, interim data from which are expected in the coming weeks.
Earlier this week, Moderna said the MHRA had started a real-time review of its experimental COVID-19 vaccine.
The EMA uses “rolling reviews” to speed up evaluations of promising drugs or vaccines during a public health emergency, by assessing data as it is submitted, rather than waiting for all data to be made available along with a formal application.
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.